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ABSTRACT
Background: A global programme to eliminate
lymphatic filariasis (GPELF) is underway, yet two key
programmatic features are currently still lacking: (1) the
extension of efforts to all lymphatic filariasis (LF)
endemic countries, and (2) the expansion of
geographic coverage of mass drug administration
(MDA) within countries. For varying levels of scale-up
of MDA, we assessed the health benefits and the
incremental cost-effectiveness ratios (ICERs)
associated with LF eradication, projected the potential
savings due to decreased morbidity management
needs, and estimated potential household productivity
gains as a result of reduced LF-related morbidity.
Methods: We extended an LF transmission model to
track hydrocele and lymphoedema incidence in order
to obtain estimates of the disability adjusted life years
(DALYs) averted due to scaling up MDA over a period
of 50 years. We then estimated the ICERs and the cost-
effectiveness acceptability curves associated with
different rates of MDA scale-up. Health systems
savings were estimated by considering the averted
morbidity, treatment-seeking behaviour and morbidity
management costs. Gains in worker productivity were
estimated by multiplying estimated working days lost
as a result of morbidity with country-specific per-
worker agricultural wages.
Results: Our projections indicate that a massive
scaling-up of MDA could lead to 4.38 million
incremental DALYs averted over a 50-year time
horizon compared to a scenario which mirrors current
efforts against LF. In comparison to maintaining the
current rate of progress against LF, massive scaling-
up of MDA—pursuing LF eradication as soon as
possible—was most likely to be cost-effective above a
willingness to pay threshold of US$71.5/DALY
averted. Intensified MDA scale-up was also associated
with lower ICERs. Furthermore, this could result in
health systems savings up to US$483 million.
Extending coverage to all endemic areas could
generate additional economic benefits through gains
in worker productivity between US$3.4 and US$14.4
billion.
Conclusions: In addition to ethical and political
motivations for scaling-up MDA rapidly, this analysis
provides economic support for increasing the intensity
of MDA programmes.
Key questions
What is already known about this topic?
▸ A key challenge for the elimination of lymphatic fil-
ariasis (LF) is the expansion of geographic cover-
age of mass drug administration programmes.
Without intense scale-up, elimination of LF will
require both more time and more treatments.
▸ Prior studies have not considered the cost-
effectiveness associated with scaling-up geo-
graphic coverage of an eradication programme,
while accounting for progress made to date in
eliminating LF.
What are the new findings?
▸ The faster geographic coverage of mass drug
administration programmes is brought to scale,
the greater the health benefits will be in terms of
disability adjusted life years averted (DALY).
▸ Extending coverage to all endemic countries,
including those that to date have not yet under-
taken mass drug administration programmes, was
most likely to be cost-effective above a willingness
to pay threshold of US$71.5/DALY averted when
scale-up occurred at the fastest rate.
Recommendations for policy and practice
▸ The Global Programme to Eliminate Lymphatic
Filariasis has been succesful to date, but it has
been recognised that coverage will have to be
scaled up substantially if the target of elimination
by 2020 is to be achieved. This analysis suggests
that more intense forms of scale-up are most
likely to be cost-effective, lending further support
to intensifying LF elimination efforts.
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INTRODUCTION
To date, smallpox is the only human infectious disease
that has been eradicated through deliberate efforts, an
accomplishment that is considered among the greatest
medical achievements in the past century.1 This success
increased interest in disease eradication as a public
health strategy, and eradication campaigns against
poliomyelitis and dracunculiasis (Guinea worm) are
currently underway. Progress against dracunculiasis indi-
cates that the concept of eradication can be applied to
parasitic infections for which vaccines are not
available.2
Disease eradication results from the permanent cessa-
tion of transmission of the causative agent of the disease
globally and the ultimate disappearance of the organism
as a free-living biological species. This is distinct from
elimination, which is the interruption of transmission in
a defined geographic area, mostly a country or a region.
Control reflects the use of interventions aimed at redu-
cing the health burden associated with transmission of a
pathogen, but does not intend to interrupt transmis-
sion.3 The decision to shift from a strategy based on
reducing the health burden to one of elimination and
progressively aiming at eradication is not to be taken
lightly.4 Since eradication is an all-or-nothing achieve-
ment, and one that will require an intensified and/or
altogether different strategy than disease control, failure
to achieve it may represent a misuse of resources. In
addition, failed attempts lead to donor fatigue with per-
sistent negative consequences.5 To provide policymakers
with guidance on whether to pursue eradication, the
concept of an Eradication Investment Case (EIC) was
developed following insights from an Ernst Strüngmann
forum on scientific advances in disease eradication.6 7
An EIC is expected to include a quantitative assessment
of the technical and biological feasibility of achieving
eradication, an assessment as to whether the health
system infrastructure is capable of delivering the inter-
ventions, and evidence of sufficient funding and polit-
ical will to support such a programme. The various
components also need to be periodically re-evaluated as
the programme progresses, since all are potentially
prone to erosion due to factors including emerging
drug resistance, weak health systems, or public and
donor fatigue.8
Further arguments for or against engaging in eradica-
tion will come from economic considerations.9 Using a
game-theoretic approach to the eradication of smallpox,
Barrett and Hoel10 were able to specify conditions
under which an eradication strategy was optimal.
Specifically, pursuing an intensive control strategy was
never optimal, if eradication was possible. Similar argu-
ments based on health economic modelling have been
made to support continued investments in the eradica-
tion of poliomyelitis.11
Lymphatic filariasis (LF) endemicity is strongly tied to
poverty12 and leads to debilitating, chronic forms of
morbidity, most notably hydrocele and lymphoedema.13
The health burden from LF is considerable, estimated at
2.77 million disability adjusted life years (DALYs) (1.8–
4.0 million) in 2010.14 Beyond affecting physical health
and productivity, LF-related morbidity also leads to
stigma and social exclusion, and impacts mental well-
being.15 Such exclusion can lead to delays in treatment
seeking, diminish prospects for marriage or employment
or interfere with the ability of school-aged children to
attend school.16–18 This, in turn, may exacerbate the link
to poverty for families with one or more infected house-
hold members.
Preventive chemotherapy represents the primary strat-
egy of the ongoing Global Programme to Eliminate
Lymphatic Filariasis (GPELF), which aims for eradica-
tion of LF by 2020.19 The strategy is based on
once-yearly mass drug administration (MDA) either with
diethylcarbamazine citrate (DEC) and albendazole
(ABZ), or, in areas where onchocerciasis is also
endemic, ivermectin (IVM) and ABZ. These compounds
kill microfilariae and affect the survivorship and/or
fecundity of adult worms.20 If MDA is provided to a
large proportion of the population (>65%) for a suffi-
cient number of years, interruption of transmission in
the targeted region is thought to be feasible.13
As LF proceeds towards elimination and eradication,
certain challenges are worthy of consideration, including
the feasibility of reaching remote populations and the
ability to maintain coverage in urban areas with dense
and mobile populations.21 An animal reservoir is not
generally thought to contribute to LF transmission,
although Brugia malayi is sometimes found in non-
human primates, cats and dogs.22 In Central African
areas coendemic with Loa loa, it remains to be seen if
the provisional strategy based on vector control and
twice-yearly MDA with ABZ will be successful.19 For the
purposes of this study we assume that eradication of LF
is feasible and the mentioned challenges can be tackled.
We previously developed scenarios that could lead to
the elimination or eradication of LF, estimated the time
it might take to reach elimination and eradication, pro-
jected the number of treatments required under each
scenario, and considered the associated financial and
economic costs.23 In the current study, we assess the
health impact in terms of disability-adjusted life years
(DALYs) averted, estimate the cost-effectiveness asso-
ciated with different intensities of scaling-up MDA, and
project the possible savings to the health system and
potential increase in worker productivity due to averted
LF-related morbidity for each of these scenarios.
METHODS
Scenarios modelled
We defined four scenarios which differ in their geo-
graphic coverage and rate of MDA scale-up. The scen-
arios were developed in an iterative consensus process
involving leading scientists, policymakers, programme
managers and other stakeholders following an analysis
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of the on-going GPELF.23 For areas co-endemic with
Wuchereria bancrofti and Loa loa we made the simplifying
assumption that whatever strategy will end up being
used in reality (eg, the provisional guidelines from the
WHO suggest bi-annual MDA of ABZ and vector
control) can be approximated in our model by annual
MDA with IVM+ALB. The current elimination scenario
is defined as the comparator scenario, mirroring the
rate of MDA scale-up seen under the GPELF thus far,
but assuming that countries that have not yet begun
MDA programmes will not do so. As we identified low
levels of geographic coverage within certain endemic
areas to be the major impediment to progress against
LF, the three eradication scenarios explore the impact of
expanding MDA to all LF endemic populations at
varying rates. Eradication I models the impact of
expanding MDA to all endemic areas at the historical
average rate of scale-up; eradication II assumes countries
scale-up geographic coverage by 20% increments each
year, and eradication III represents the best-case scen-
ario, whereby all countries expand coverage to their
entire at-risk population immediately. See the SI and
Kastner et al23 for further details.
Estimates of DALYs
We extended a previously published deterministic
model, EpiFil,24 which simulates filariasis transmission by
either Anopheles species or Culex species vectors.25 See
the SI for details on how the model was expanded to
include chronic disease states.
We translated the incidence of chronic disease to
DALYs, which, in the case of LF, are composed of the
years of life lived with a disability (YLD) multiplied by
the disability weight (DW). We determined the number
of new hydrocele and lymphoedema cases in a given
time period and assigned YLDs at that point based on
the individual’s remaining life expectancy.26 Per conven-
tion, no distinction in the DW was made between lym-
phoedema and hydrocele, and symptomatic cases were
assigned a DW of 0.11.27 Age-weighting was not consid-
ered in this study, but DALYs were discounted at 3% per
year. Further details on the calculations are provided in
the SI. The DALYs were estimated for a period of
50 years to capture the long-term health benefits of
interrupting transmission.
Estimates of financial and economic costs
Programmatic costs were estimated from the perspective
of an LF-endemic country’s health system, with future
costs discounted at 3%. Activities considered in the cost
estimates included advocacy, capacity strengthening,
coordination and strengthening partnerships, data man-
agement, on-going surveillance, monitoring, evaluation
and supervision, drug delivery, and administration. Costs
for mapping, running post-MDA transmission assess-
ment surveys and increased surveillance in areas of L.
loa prevalence were also taken into account. A summary
of the costing methodology is provided in the online
supplementary material.
Cost-effectiveness analysis
In order to evaluate the cost-effectiveness of eradication,
the DALY projections for each country in each scenario
were paired with country-specific cost estimates. With
the elimination scenario as the reference case against
which all other scenarios could be compared, cost-
effectiveness was assessed using incremental cost-
effectiveness ratios (ICERs). For each simulation, the
monetary net benefits (MNB) were calculated as the
mean incremental DALYs averted multiplied by the
decision makers’ maximum willingness to pay for a
DALY averted minus the mean incremental cost for the
scenario.28 Cost-effectiveness acceptability curves were
used to graphically depict the probability for each scen-
ario to be cost-effective at various willingness-to-pay
thresholds.
Potential health system savings and worker productivity
losses
To assess the potential health systems savings due to
averted morbidity management, we followed the
approach of Chu et al and assumed that on average 40%
(20–50%) of hydrocele patients and 50% (30–55%) of
patients with lymphoedema seek treatment annually. We
further assumed acute adenolymphangitis (ADL) to
occur about twice per year (0–7 times) in 70% (45–
90%) of hydrocele patients, and four (0–7 times) times
annually for 95% (90–95%) of patients with lymphoe-
dema.29 Since it remains uncertain to what extent treat-
ment with DEC and ABZ or IVM and ABZ reduces
clinical manifestations, we assume treatment seeking
remains at the same level during the course that patients
remain symptomatic. The estimated savings are there-
fore possibly conservative.
Health systems savings were then estimated by combin-
ing the averted incidence of morbidity, frequency of
ADL episodes and treatment-seeking behaviour paired
with country-specific costs for a consultation at a primary
health centre with 50% population coverage, taken from
the most recent update of the WHO CHOICE data-
base.30 Parameter uncertainty was considered by taking
500 random estimates within each parameter range,
assuming normal distributions for treatment-seeking
behaviour and triangular distributions for ADL episodes.
Using a pre-established methodology, we also deter-
mined the impact that LF eradication could have on
worker productivity.29 To assess the potential worker
productivity increase, we assumed ADL episodes to last
4 days on average (1–9 days), and cause a 75% (50–
93%) reduction in productivity for their duration.
LF-related morbidity was assumed to decrease the
amount of productive working days by 15% (13–17%)
for hydrocele patients and 20% (15–22%) for those with
lymphoedema. We monetarily valued possible gains in
worker productivity by taking the number of working
Stone CM, et al. BMJ Glob Health 2016;1:e000021. doi:10.1136/bmjgh-2015-000021 3
BMJ Global Health
group.bmj.com on April 7, 2016 - Published by http://gh.bmj.com/Downloaded from 
days lost due to LF-related morbidity paired with
country-specific (when available) or region-specific daily
per-worker agriculture wages given by the World Bank’s
World Development Indicators Online, inflated to 2012.
Other databases may provide different estimates to value
the productivity of people with LF, many of whom are
subsistence farmers.29 Uncertainty in the
productivity-related parameter estimates was therefore
incorporated by drawing 500 random samples from each
range assuming normal distributions. All results were dis-
counted at 3%.
Role of the funding source
The study sponsor had no role in study design; in the
collection, analysis and interpretation of data; in the
writing of the report; and in the decision to submit the
paper for publication.
RESULTS
Estimates of DALYs
The intensity of MDA scale-up greatly impacts popula-
tion health (figure 1). With elimination as the compara-
tor, extending MDA to all endemic countries
(eradication I) results in approximately 1.72 million
DALYs averted (95% Credible Interval (CrI) 1.09–2.61
million) over a 50-year time horizon. In contrast, intensi-
fying geographic coverage in all countries (eradication
III) leads to approximately 4.38 million DALYs averted
(95% CrI 2.78–6.5 million) over the same timeframe.
Thus, there are considerable gains to achieve by more
intensely scaling-up MDA (table 1).
The incremental health impacts by country, expressed
as DALYs averted per 100 000 people, are depicted for
the eradication I scenario compared to the elimination
scenario, eradication II compared to eradication I and
eradication III compared to eradication II (figure 2).
The comparison between eradication I and the elimin-
ation scenario illustrates that the majority of the gains
from extending MDA to all endemic countries are con-
centrated in Central Africa. The heterogeneous results
within these countries are largely due to demographic
patterns that affect the DALY estimates, such as age com-
position, life expectancy and population growth rates.
The gains from increasing the rate of MDA scale-up are
more evenly spread out among countries (eradication II
vs I, and III vs II).
Cost-effectiveness analysis
The estimated ICER for the eradication III scenario is
approximately US$73/DALY averted (95% CrI US$47.7–
US$109.8/DALY averted; figures 3 and 4). In contrast,
the eradication I and eradication II scenarios are higher,
at US$219/DALY averted (95% CrI US$142.7–US
$322.7/DALY averted) and US$121/DALY averted (95%
CrI US$79.5–US$177.7/DALY averted), respectively.
Against the elimination scenario, all eradication scen-
arios end in the northeast quadrant of the incremental
cost-effectiveness plane (figure 3), which implies an
increase in DALYs averted at increased cost.31
Correspondingly, and as shown by the cost-effectiveness
acceptability curve, if the willingness to pay threshold
would surpass US$71.5/DALY averted, scale-up of MDA
to all at-risk populations in all endemic countries should
be pursued as quickly as possible (figure 5).
Potential health system savings and worker productivity
losses
Unsurprisingly, reaching LF eradication sooner was
found to correspond to increased health systems savings,
due to decreased morbidity management, ranging from
US$140 million (95% CrI US$53.8–US$260.3m) in the
eradication I scenario to US$483 million (95% CrI US
$219.1–US$902.6m) in eradication III (figure 6).
Potential savings to the health system, however, were
dwarfed by possible gains in worker productivity, which
ranged from approximately US$3.4 billion (95% CrI US
$2.03–US$5.36bn) under the eradication I scenario to
US$14.4 billion (95% CrI US$8.58–US$22.02 billion) in
the eradication III scenario (figure 6). Importantly, all
increased with increasing rates of MDA scale-up, further
supporting the conclusion from the cost-effectiveness
analysis.
DISCUSSION
LF could become the first vector-borne disease to be
eradicated. While the GPELF has made notable pro-
gress thus far, in order to achieve eradication, the pro-
gramme needs to be extended to several endemic
countries. Moreover, if the goal of global elimination as
a public health problem by 2020, as specified in the
London Declaration,32 is to occur, the scale-up of MDA
Figure 1 Cumulative number of DALYs averted over time
per eradication scenario compared to the elimination scenario.
DALY, disability adjusted life years.
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to cover all populations at risk needs to be greatly
intensified.
Here, we estimate that the impact on the health
burden due to LF will increase with the rate of MDA
scale-up, since DALYs averted have a longer time period
to accrue when transmission is interrupted earlier. This
highlights the importance of measuring costs and bene-
fits of interventions over a long time horizon, as well as
the benefits of integrating disease transmission, eco-
nomic and demographic models.
Intensifying the rate of MDA scale-up to eradicate LF
is clearly supported on economic grounds. Our analysis
Table 1 Summary of key results with 95% Credible Intervals
Elimination Eradication I Eradication II Eradication III
Number of treatments
(millions)
3.41 (3.18–3.53) 4.66 (4.41–4.90) 4.37 (4.13–4.59) 4.16 (3.92–4.38)
DALYs averted (millions)* – 1.72 (1.09–2.62) 2.98 (1.90–4.45) 4.38 (2.79–6.50)
Financial costs (millions
USD)
929.2 (883.5–971.5) 1289.4 (1226.7–1344.9) 1273.5 (1208.9–1331.4) 1234.9 (1172.3–1299.8)
Economic costs (billions
USD)
5.19 (4.91–5.45) 7.91 (7.50–8.300) 7.97 (7.55–8.37) 7.53 (7.12–7.94)
ICER (USD/DALY
averted)*
– 219.0 (142.65–322.72) 120.7 (79.47–177.70) 72.94 (47.74–109.80)
Potential savings to health
system (millions USD)*
– 139.9 (63.8–260.3) 335.6 (152.2–626.8) 483.4 (219.1–902.6)
Potential gains in worker
productivity (billions USD)*
– 3.41 (2.03–5.36) 10.06 (5.98–15.50) 14.43 (8.58–22.02)
*Measured against the elimination scenario as the comparator.
DALY, disability adjusted life years; ICER, incremental cost-effectiveness ratios.
Figure 2 Cumulative number of
DALYs averted per 100 000
persons after 50 years per
country, comparing the different
scenarios to each other. DALY,
disability adjusted life years.
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suggests that above a willingness to pay threshold of US
$71.5/DALY averted, pursuing eradication at the highest
level of MDA scale-up is the most likely to provide the
greatest net benefits and therefore provide the most
value for money. To put this in perspective, a willingness
to pay of US$150/DALY averted has been suggested for
low and middle income countries as acceptable.33 While
decision makers are not bound by this threshold, our
analysis indicates that LF eradication would generally be
considered cost-effective, assuming the rate of MDA
scale-up is sufficient. If instantaneous scale-up (eradica-
tion III) is shown not to be feasible, the ICER of the
eradication II scenario (rapid scale-up) remains low at
US$121/DALY averted. Only at the slowest level of
scale-up does the ICER fall above this threshold, adding
further urgency to intensifying the rate of scale-up.
Others have used the Gross National income per capita
for low income counties of US$1035 as a threshold,34 by
which measure all eradication scenarios are considered
cost-effective. Cost-effectiveness as a measure of effi-
ciency is typically applied to interventions or health pro-
grammes. Additionally, it has been suggested that less
efficient programmes may be considered in the case of
eradication (as opposed to disease control) pro-
grammes, due to a host of additional outcomes that are
typically not captured in cost-effectiveness analyses.35
These could include the threats of resistance, insecurity
of long-term funding, or implications for economic
growth.36
Other considerations influence the cost-effectiveness
of LF eradication. Depending on the perspective taken,
the benefits that are expected to arise due to health
systems savings and gains in worker productivity could
be taken into account, which would further increase the
dominance of the eradication III scenario. We did not
consider certain aspects of morbidity management, such
as the need for hydrocele surgeries, which would dimin-
ish over time as transmission is interrupted. The eco-
nomic benefits of eradication could therefore be greater
than estimated here. Likewise, our estimates of gains in
Figure 3 Incremental cost-effectiveness plane and 95% CI
ellipses with incremental financial costs associated with MDA
programmes and incremental disability adjusted life years
averted, comparing the three eradication scenarios to the
comparator scenario. DALY, disability adjusted life years;
MDA, mass drug administration.
Figure 4 Incremental cost-effectiveness ratios associated
with each of the scenarios, with elimination as the comparator.
DALY, disability adjusted life years.
Figure 5 Cost-effectiveness acceptability curve for the four
scenarios highlighting the uncertainty around
cost-effectiveness ratios. Above the cost-effectiveness
threshold of $71.50/DALY the probability of the eradication III
scenario being more cost-effective than the elimination
scenario increases. When eradication III is a realistic option,
eradication scenarios I and II are never the most
cost-effective. DALY, disability adjusted life years.
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productivity are likely conservative, because they were
based on the time lost due to LF-related morbidity and
agricultural wages, rather than on direct estimates of
output and productivity loss (which are reported to be
greater for LF, though data is scarce).29 By tracking mor-
bidity only for hydrocele and lymphoedema, but not
subclinical outcomes such as lymphatic dilation, or clin-
ical manifestations such as ADL or tropical pulmonary
eosinophilia, or a potential for excess mortality (either
due to a lack of data or a lack of disability weights), we
underestimate the true burden of disease.37 There are
some epidemiological aspects that we did not consider,
such as recrudescence of infections in areas following
elimination due to migration. By ignoring this possibility,
we made the implicit assumption that international
movement among endemic populations was limited.
Relaxing this assumption would require a metapopula-
tion model and an investigation of human migration
and commuting patterns in LF-endemic regions.
However, previous studies in which similar mechanisms
were considered have only added to the growing support
for pursuing eradication.10 11
Further aspects which could interfere with the ability
to maintain sufficiently high MDA coverage include
insufficient political will, inadequate health infrastruc-
ture, logistical issues and the potential of systematic non-
compliance. The development of drug resistance, as has
been documented in animal systems,38 could also
present complications. Further and equally important,
in areas where W. bancrofti is co-endemic with L. loa, it
remains to be seen how effective biannual distribution
of ABZ by itself or together with long-lasting insecticidal
nets will be. We have assumed that the strategy employed
in these areas would be as effective as MDA with IVM
and ABZ, and as unlikely to lead to resistance. However,
if this is not the case, and an alternative strategy requires
a larger investment or a prolonged campaign, the ICERs
of the eradication scenarios will increase. We have like-
wise not accounted for any progress in interrupting LF
transmission resulting from bed net programmes target-
ing malaria, although modelling suggests such methods
are highly efficacious against LF.39 40 If vector control is
going to be part of a strategy against LF in certain
regions, cost estimates should likewise incorporate this
intervention. Further, it is worth noting that our esti-
mates of progress made to the current time were
informed by the WHO PCT Databank, as described in
Kastner et al.23 It has been pointed out that these self-
reported values are sometimes overestimates of the true
coverage.41 Accounting for this bias would likely
decrease the ICERs of the eradication scenarios.
Currently, data to improve on these estimates is unavail-
able but additional modelling work, more focused on
individual districts based on local data, may be enligh-
tening. Such work will be particularly valuable in identi-
fying more effective strategies for dealing with endemic
districts where progress seems to be lagging. Such strat-
egies could potentially include novel technologies, or
novel combinations, such as a proposed triple-drug treat-
ment regime.42
Additionally, we assumed that endemic countries
implemented MDA programmes for a fixed duration
resulting in a high probability of achieving elimination
(ie, where >97.5% of simulations reached elimination).23
A more dynamic decision process, whereby a shorter
duration is followed by surveys and possible additional
rounds of MDA until elimination is certified may be
closer to reality, but beyond the scope of this global-level
exercise.
Finally, our strategies assumed that all endemic coun-
tries included in the different scenarios are committed
to elimination, and would not pursue a less ambitious
goal, such as disease control only. It is plausible,
however, for some countries to only target populations
Figure 6 Cumulative cost savings and averted losses over 50 years associated with LF eradication scenarios. Left: potential
cost savings to LF endemic health systems due to decreased need for morbidity management practices; right: averted
productivity losses due to eradication. LF, lymphatic filariasis.
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that live in moderate to high transmission zones, but not
the greater number of people in low transmission areas
where chronic disease is much less prevalent. A previous
study indeed suggests that cost-effectiveness may improve
if communities with microfilaria prevalence above 3.55%
are first treated through a sequential strategy based first
on control and a later shift of programme goals towards
elimination.43 Ordering the treatment districts by inten-
sity could thus lead to further increases in cost-
effectiveness of our eradication scenarios.
In conclusion, this study suggests that eradication of
LF is likely a cost-effective strategy and that if pursued,
scaling up MDA as rapidly as feasible will result in
increases in value.
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